Innovative Partnership to Transform IBS Management in the U.S.
Innovative Collaboration to Enhance IBS Management
- Expands Marketing of Non-Drug IBS Symptom Management Test
- Key Milestone in Biomerica’s Commercialization Strategy
Biomerica, Inc. has announced an exciting collaboration with Henry Schein, a leading provider of healthcare solutions. This new marketing services agreement focuses on promoting Biomerica’s cutting-edge inFoods® Irritable Bowel Syndrome (IBS) test across the United States, except for New York State. This partnership aims to enhance the lives of individuals suffering from IBS by providing a non-drug solution.
Henry Schein is recognized as one of the nation’s trusted distributors with over 400 sales representatives. Their extensive distribution network is perfectly positioned to reach primary care and gastroenterology clinics, offering invaluable support for the adoption of the innovative inFoods® IBS test. With more than nine decades of experience in healthcare innovations and impressive sales figures over $12 billion in the last fiscal year, Henry Schein is set to significantly contribute to the growth of this pioneering diagnostic therapy.
“We are ecstatic to partner with Henry Schein to deliver the inFoods® IBS test to a broader audience of patients and healthcare providers,” expressed Zack Irani, CEO of Biomerica. “Henry Schein's national presence and historical success in introducing innovative medical products will expedite the acceptance of our personalized, non-drug treatment for those managing IBS.”
A Notable Clinical Study in Gastroenterology
A groundbreaking multicenter clinical investigation has recently been published in a prominent gastroenterology journal, highlighting the effectiveness of the inFoods® IBS test. This double-blinded study, which is the most extensive of its kind, demonstrated significant improvements in patients:
- 59.6% of patients who avoided certain trigger foods achieved the FDA’s criterion for reducing abdominal pain, compared to 42.2% in the control group.
- In patients diagnosed with IBS-C, 67.1% reached positive results versus 35.8% in those who followed standard treatments.
- Among IBS-M patients, a notable 66% experienced improvement compared to just 29.5% in the control group.
These promising outcomes indicate the inFoods® IBS test as the only targeted therapy demonstrating significant efficacy in managing IBS-M, a group that has been historically overlooked by conventional remedies. The study was conducted at leading institutions, including the Cleveland Clinic and Mayo Clinic.
The Importance of Addressing IBS
Irritable bowel syndrome is a common ailment, affecting roughly 10% to 15% of adults in the United States. Patients often report a diminished quality of life and lowered productivity levels. Typical symptoms include painful abdominal cramps, and specific foods can exacerbate their conditions, leading to frustrating flare-ups.
Discovering the Benefits of inFoods® IBS
The inFoods® IBS test offers a revolutionary approach by pinpointing individual food intolerances that trigger IBS symptoms, including abdominal pain and bloating. Utilizing a simple finger-prick blood test, healthcare providers can recommend personalized dietary adjustments tailored to each patient’s unique immune responses, thereby offering an innovative, data-driven pathway for relief from IBS symptoms.
Biomerica has developed this Laboratory Developed Test (LDT) within a CLIA-certified lab, ensuring both safety and accuracy in the testing process.
About Biomerica, Inc. (NASDAQ: BMRA)
Biomerica is a global biomedicine firm that specializes in creating and marketing advanced diagnostic tools and therapies dedicated to addressing medical conditions efficiently. Their focus on gastrointestinal health has led to the development of a variety of diagnostic and therapeutic products aimed at improving health outcomes while minimizing healthcare expenditures.
Biomerica understands the importance of collaboration and consumer needs, which is underscored by their recent partnership with Henry Schein. As they continue to innovate and expand their product offerings, the future looks promising for both the company and the patients they serve.
Corporate Contact:
Zack Irani | CEO
p. 949.645.2111
www.biomerica.com
Frequently Asked Questions
What is the inFoods® IBS test?
The inFoods® IBS test is a diagnostic tool that identifies food triggers causing IBS symptoms, enabling personalized dietary changes for symptom relief.
How does the partnership with Henry Schein benefit patients?
Henry Schein's extensive reach will help enhance access to the inFoods® IBS test, leading to more patients receiving this innovative non-drug therapy.
What are the results of the clinical study related to the inFoods® IBS test?
The study showed that patients who eliminated trigger foods experienced significant reductions in abdominal pain, highlighting the test's effectiveness.
How does the inFoods® IBS test work?
The test requires a simple finger-stick blood sample to identify individual dietary triggers, allowing for tailored nutritional recommendations.
Why is there a need for targeted IBS therapies?
IBS affects a significant portion of the population, with many patients experiencing inadequate relief from traditional treatments, emphasizing the necessity for more effective solutions.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
